+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis



Efficacy and economics of topical calcineurin inhibitors for the treatment of atopic dermatitis



American Journal of Clinical Dermatology 7(4): 213-222



Atopic dermatitis is a chronic, relapsing inflammatory skin disease that frequently affects infants and children. The worldwide prevalence of atopic dermatitis is estimated to be 5-20% of the pediatric population. Studies have shown that atopic dermatitis is associated with considerable economic costs and decreased quality of life. There is no proven curative therapy at present for atopic dermatitis; first-line therapy has generally consisted of dry skin care, avoidance of triggers, application of topical corticosteroids, and administration of histamine H1 receptor antagonists (antihistamines) and oral antibacterials as appropriate. Topical corticosteroids, while effective in many patients, carry the concern of local and systemic adverse effects. As a result, physicians and patients are reluctant to utilize stronger topical corticosteroids in certain areas of the body and for prolonged periods of time. The purpose of this article is to review the efficacy and economics of topical calcineurin inhibitors in the treatment of atopic dermatitis. This new class of agents (specifically tacrolimus ointment and pimecrolimus cream) represents an exciting advance in the treatment of atopic dermatitis. Clinical data show that topical calcineurin inhibitors are effective and do not cause the adverse effects associated with topical corticosteroids. Several studies have provided evidence that topical calcineurin inhibitors positively affect the quality of life of patients and their caregivers. Compared with branded topical corticosteroids and previous standards of care, topical calcineurin inhibitors appear to be a cost-effective treatment option. Drawing comparisons between tacrolimus and pimecrolimus is difficult because definitive head-to-head comparative studies involving these drugs have not been conducted.

(PDF emailed within 0-6 h: $19.90)

Accession: 048918511

Download citation: RISBibTeXText

PMID: 16901181

DOI: 10.2165/00128071-200607040-00002


Related references

Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. American Journal of Clinical Dermatology 6(2): 65-77, 2005

Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. American Journal of Therapeutics 16(3): 264-273, 2009

Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas. Current Medical Research and Opinion 24(4): 985-994, 2008

Topical Calcineurin Inhibitors in the Treatment of Atopic Dermatitis. American Journal of Clinical Dermatology 5(4): 267-279, 2004

Systematic review on the efficacy, safety, and cost-effectiveness of topical calcineurin inhibitors in atopic dermatitis. Dermatitis 26(3): 122-132, 2016

The treatment of atopic dermatitis in adults with topical calcineurin inhibitors. Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete 54(5): 424-431, 2003

Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. PharmacoTherapy 27(7): 1020-1028, 2007

Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatric Drugs 15(4): 303-310, 2013

Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis. Dermatology 211(2): 174-187, 2005

A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis. Medgenmed 8(4): 8, 2007

Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks?. Mmw Fortschritte der Medizin 145(29-30): 62-62, 2003

Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues. Journal der Deutschen Dermatologischen Gesellschaft 10(3): 167-172, 2013

Topical calcineurin inhibitors in the treatment of atopic dermatitis: a meta-analysis of current evidence. American Journal of Clinical Dermatology 5(4): 267-279, 2004

Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema. British Journal of Dermatology 161(2): 219-220, 2009

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. Journal of Dermatological Treatment 21(3): 144-156, 2010